ALNY – Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.ALNY
$333.00Name : Alnylam Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $44,431,495,168.00
EPSttm : 2.33
Alnylam Pharmaceuticals, Inc.
$333.00
3.38%$10.89
ALNY — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
3.85
Margin Of Safety %
-12
Put/Call OI Ratio
0.37
EPS Next Q Diff
0.89
EPS Last/This Y
6.86
EPS This/Next Y
4.95
Price
333.01
Target Price
444.73
Analyst Recom
1.71
Performance Q
-16.39
Upside
-76.2%
Beta
0.38
Ticker: ALNY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-17 | ALNY | 320.49 | 0.39 | 0.24 | 24566 |
| 2026-03-18 | ALNY | 314.93 | 0.33 | 1.32 | 23799 |
| 2026-03-19 | ALNY | 311 | 0.32 | 0.11 | 23643 |
| 2026-03-20 | ALNY | 311.17 | 0.31 | 0.33 | 23418 |
| 2026-03-23 | ALNY | 306.6 | 0.37 | 0.78 | 17743 |
| 2026-03-24 | ALNY | 308.05 | 0.37 | 3.25 | 17843 |
| 2026-03-25 | ALNY | 328.8 | 0.38 | 0.69 | 18112 |
| 2026-03-26 | ALNY | 328.39 | 0.37 | 0.12 | 18813 |
| 2026-03-27 | ALNY | 317.37 | 0.37 | 0.06 | 18688 |
| 2026-03-30 | ALNY | 315.95 | 0.36 | 0.72 | 19197 |
| 2026-03-31 | ALNY | 330.77 | 0.36 | 0.35 | 19817 |
| 2026-04-01 | ALNY | 328.59 | 0.36 | 0.85 | 20028 |
| 2026-04-02 | ALNY | 318.84 | 0.36 | 0.11 | 20077 |
| 2026-04-06 | ALNY | 330.47 | 0.35 | 0.89 | 20585 |
| 2026-04-08 | ALNY | 327.23 | 0.36 | 0.12 | 21296 |
| 2026-04-09 | ALNY | 321.18 | 0.36 | 0.06 | 21295 |
| 2026-04-13 | ALNY | 333.28 | 0.37 | 0.23 | 22169 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-17 | ALNY | 320.26 | 15972.7 | 529.5 | 9.56 |
| 2026-03-18 | ALNY | 314.77 | 15972.7 | 504.5 | 9.56 |
| 2026-03-19 | ALNY | 311.00 | 15972.7 | 767.1 | 9.56 |
| 2026-03-20 | ALNY | 312.17 | 15972.7 | 789.3 | 9.56 |
| 2026-03-23 | ALNY | 306.64 | 15636.4 | 759.1 | 9.43 |
| 2026-03-24 | ALNY | 307.99 | 15636.4 | 790.4 | 9.43 |
| 2026-03-25 | ALNY | 328.79 | 15636.4 | 879.6 | 9.43 |
| 2026-03-26 | ALNY | 328.17 | 15636.4 | 781.9 | 9.43 |
| 2026-03-27 | ALNY | 317.43 | 15636.4 | 738.0 | 9.43 |
| 2026-03-30 | ALNY | 316.04 | 15636.4 | 778.3 | 9.43 |
| 2026-03-31 | ALNY | 330.92 | 15375.0 | 850.6 | 9.25 |
| 2026-04-01 | ALNY | 328.65 | 15375.0 | 774.7 | 9.25 |
| 2026-04-02 | ALNY | 318.79 | 15375.0 | 741.5 | 9.25 |
| 2026-04-06 | ALNY | 330.40 | 15375.0 | 835.4 | 9.25 |
| 2026-04-07 | ALNY | 319.47 | 15375.0 | 737.4 | 9.25 |
| 2026-04-08 | ALNY | 327.15 | 15375.0 | 809.2 | 9.25 |
| 2026-04-09 | ALNY | 321.28 | 15375.0 | 750.1 | 9.25 |
| 2026-04-10 | ALNY | 322.21 | 15375.0 | 788.3 | 9.25 |
| 2026-04-13 | ALNY | 333.01 | 15375.0 | 832.0 | 9.25 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-17 | ALNY | -10.20 | -0.72 | 3.48 |
| 2026-03-18 | ALNY | -10.20 | -0.72 | 3.48 |
| 2026-03-19 | ALNY | -10.20 | -0.72 | 3.48 |
| 2026-03-20 | ALNY | -10.20 | -0.72 | 3.48 |
| 2026-03-23 | ALNY | -10.20 | -0.71 | 3.48 |
| 2026-03-24 | ALNY | -10.20 | -0.71 | 3.48 |
| 2026-03-25 | ALNY | -10.20 | -0.71 | 3.32 |
| 2026-03-26 | ALNY | -10.20 | -0.71 | 3.32 |
| 2026-03-27 | ALNY | -10.20 | -0.71 | 3.32 |
| 2026-03-30 | ALNY | -10.20 | -0.71 | 3.32 |
| 2026-03-31 | ALNY | -10.20 | -0.71 | 3.32 |
| 2026-04-01 | ALNY | -10.20 | -0.71 | 3.32 |
| 2026-04-02 | ALNY | -10.20 | -0.71 | 3.32 |
| 2026-04-06 | ALNY | -8.62 | -0.71 | 3.32 |
| 2026-04-07 | ALNY | -8.90 | -0.71 | 3.32 |
| 2026-04-08 | ALNY | -8.90 | -0.71 | 3.32 |
| 2026-04-09 | ALNY | -8.90 | -0.71 | 3.32 |
| 2026-04-10 | ALNY | -8.90 | -0.71 | 3.32 |
| 2026-04-13 | ALNY | -8.90 | -0.67 | 3.85 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.25
Avg. EPS Est. Current Quarter
1.53
Avg. EPS Est. Next Quarter
2.14
Insider Transactions
-8.9
Institutional Transactions
-0.67
Beta
0.38
Average Sales Estimate Current Quarter
1124
Average Sales Estimate Next Quarter
1321
Fair Value
291.59
Quality Score
89
Growth Score
64
Sentiment Score
56
Actual DrawDown %
32.8
Max Drawdown 5-Year %
-42.5
Target Price
444.73
P/E
147.53
Forward P/E
31.84
PEG
0.41
P/S
11.89
P/B
55.86
P/Free Cash Flow
94.9
EPS
2.26
Average EPS Est. Cur. Y
9.25
EPS Next Y. (Est.)
14.2
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
8.45
Relative Volume
0.71
Return on Equity vs Sector %
12.4
Return on Equity vs Industry %
29
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.3
EBIT Estimation
832
◆
ALNY
Healthcare
$333.00
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
55.1
Range 1M
89.9%
Sup Dist
4.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
186.9%
EPS NY
56.5%
52W%
39.3%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+27.6% upside
Upside
+27.6%
Quality
89
MoS
-12%
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2500
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ALNY
Latest News
—
Caricamento notizie per ALNY…
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading